Neutralising antibody responses to emerging SARS ‐ CoV ‐2 omicron sub‐variants are enhanced in persons with hybrid immunity
Clinical & Translational Immunology · 2026-04 · 15 (4)
DOI: 10.1002/cti2.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 16.04.2026. Verfasst von Sharon L Walmsley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine University Health Network Toronto ON Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Public Health Agency of Canada, Canadian Institutes of Health Research, University Health Network Foundation.
Abstract (Originalsprache)
Objectives
To assess neutralizing antibody responses to emerging SARS‐CoV‐2 variants Methods We explored SARS‐CoV‐2 neutralizing antibodies in140 adults participating in a longitudinal study of antibody responses to COVID vaccines. Participants reported monthly on vaccine doses, and SARS‐CoV‐2 infections. Serum was collected in December 2023 and April 2024 to determine neutralizing antibody to Wuhan ancestral strain and Omicron XBB.1.5 and JN.1 subvariants. Multivariate analysis assessed protective factors against a new SARS‐CoV‐2 infection between the two sampling times and 10 months follow up.
Results
74% had hybrid immunity and 26% vaccine only immunity at study entry. A neutralizing antibody response was detected in 99% to Wuhan ancestral strain compared to 86% and 79% respectively to Omicron XBB.1.5 and JN.1 subvariants. For those with detectable antibodies the levels decayed, faster in those with vaccine only immunity and to the JN.1 subvariant. Neither the presence or the level of neutralizing antibody to JN.1 was associated with protection with a new SARS‐Cov‐2 infection over the 10‐month follow up period.
Conclusion
Neutralizing antibody levels to Omicron JN.1 subvariant were identified in 79% overall but in only 56% with vaccine only immunity. The presence or level was not associated with protection form a new SARS‐CoV‐2 infection over 10‐months. This data supports the development of pan‐coronavirus vaccine to expand protection against emerging variants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine University Health Network Toronto ON Canada.
- Faculty of Medicine University of Toronto Toronto ON Canada.
- Immunodeficiency Clinic University Health Network Toronto ON Canada.
- Biostatistical Research Unit University Health Network Toronto ON Canada.
- Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital Toronto ON Canada.
- Department of Molecular Genetics University of Toronto Toronto ON Canada.
ORCID-Profile: Majid Nabipoor, Leif Erik Lovblom
Förderung
- Public Health Agency of Canada
- Canadian Institutes of Health Research
- University Health Network Foundation
Zitieren
APA
Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., & Gingras, A. C. (2026). Neutralising antibody responses to emerging SARS ‐ CoV ‐2 omicron sub‐variants are enhanced in persons with hybrid immunity. Clinical & Translational Immunology, 15(4). https://doi.org/10.1002/cti2.70095
Vancouver
Walmsley SL, Nabipoor M, Qi F, Lovblom LE, Ravindran R, Colwill K, et al. Neutralising antibody responses to emerging SARS ‐ CoV ‐2 omicron sub‐variants are enhanced in persons with hybrid immunity. Clinical & Translational Immunology. 2026;15(4). doi:10.1002/cti2.70095
BibTeX
@article{Walmsley2026,
author = {Walmsley, Sharon L and Nabipoor, Majid and Qi, Freda and Lovblom, Leif Erik and Ravindran, Rizani and Colwill, Karen and Gingras, Anne Claude},
title = {Neutralising antibody responses to emerging SARS ‐ CoV ‐2 omicron sub‐variants are enhanced in persons with hybrid immunity},
journal = {Clinical & Translational Immunology},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cti2.70095}
}
EUVIMED